399 related articles for article (PubMed ID: 27727279)
1. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
2. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E; Howlett J; Porter L; Truman L; Heywood J; Kennet J; Arbon EL; Anselmiova K; Walker NM; Atkar R; Pekalski ML; Rytina E; Evans M; Wicker LS; Todd JA; Mander AP; Bond S; Waldron-Lynch F
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282826
[TBL] [Abstract][Full Text] [Related]
3. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.
Waldron-Lynch F; Kareclas P; Irons K; Walker NM; Mander A; Wicker LS; Todd JA; Bond S
BMJ Open; 2014 Jun; 4(6):e005559. PubMed ID: 24898091
[TBL] [Abstract][Full Text] [Related]
4. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
5. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
6. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
[TBL] [Abstract][Full Text] [Related]
7. Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial.
Zhao TX; Kostapanos M; Griffiths C; Arbon EL; Hubsch A; Kaloyirou F; Helmy J; Hoole SP; Rudd JHF; Wood G; Burling K; Bond S; Cheriyan J; Mallat Z
BMJ Open; 2018 Sep; 8(9):e022452. PubMed ID: 30224390
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
9. Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.
Cutler AJ; Oliveira J; Ferreira RC; Challis B; Walker NM; Caddy S; Lu J; Stevens HE; Smyth DJ; Pekalski ML; Kennet J; Hunter KMD; Goodfellow I; Wicker LS; Todd JA; Waldron-Lynch F
Wellcome Open Res; 2017; 2():28. PubMed ID: 28815218
[TBL] [Abstract][Full Text] [Related]
10. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.
Marcovecchio ML; Wicker LS; Dunger DB; Dutton SJ; Kopijasz S; Scudder C; Todd JA; Johnson PRV
Wellcome Open Res; 2020; 5():49. PubMed ID: 32399500
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
[TBL] [Abstract][Full Text] [Related]
13. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
[TBL] [Abstract][Full Text] [Related]
14. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Heywood J; Evangelou M; Goymer D; Kennet J; Anselmiova K; Guy C; O'Brien C; Nutland S; Brown J; Walker NM; Todd JA; Waldron-Lynch F
Trials; 2015 Mar; 16():86. PubMed ID: 25881192
[TBL] [Abstract][Full Text] [Related]
15. FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.
Viisanen T; Gazali AM; Ihantola EL; Ekman I; Näntö-Salonen K; Veijola R; Toppari J; Knip M; Ilonen J; Kinnunen T
Front Immunol; 2019; 10():19. PubMed ID: 30723474
[TBL] [Abstract][Full Text] [Related]
16. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A; Bensimon G; Payan CA; Jacqueminet S; Bourron O; Nicolas N; Fonfrede M; Rosenzwajg M; Bernard C; Klatzmann D
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):295-305. PubMed ID: 24622415
[TBL] [Abstract][Full Text] [Related]
17. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
[TBL] [Abstract][Full Text] [Related]
18. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
[TBL] [Abstract][Full Text] [Related]
19. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of CD39 on memory regulatory T cells in type 1 diabetes patients.
Jin X; Zhang C; Gong L; Li H; Wang Y; Li Q; Li H
J Diabetes; 2019 Jun; 11(6):440-448. PubMed ID: 30318734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
